Highlighted Article


Real-World PFS for ALK TKIs in ALK+ NSCLC Patients

Mohammad Jahanzeb, et al., The Oncologist

Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.



Dr. Don DizonDiscussions with Don S. Dizon

Don S. Dizon is the Director of Women's Cancers at Lifespan Cancer Institute, Founder of The Oncology Sexual Health First Responders Clinic at Lifespan Cancer Institute, and Director of Medical Oncology at Rhode Island Hospital. Dr. Dizon is a Professor of Medicine at the Warren Alpert Medical School of Brown University.


Don Dizon learns about Ginny Mason's experiences as a breast cancer survivor, patient advocate, and nonprofit leader in this month's blog post.
In this month's blog post, Don Dizon and his colleague Mary Anne Fenton discuss her career in oncology and how the profession has changed over the past 20 years.
In this month's blog, Don Dizon and patient advocate Stacey Tinianov reflect on the power words can have when communicating about cancer with patients. They also discuss how the meaning of words can be fluid and dependent on individual context.


As we monitor and respond to the COVID-19 outbreak, we at AlphaMed Press know how important every update and new piece of information is to reaching the goal of ending this pandemic. Below you can find helpful links to the latest research and findings.